Journal of the Chinese Medical Association : JCMA · 2013
Circulating platelet-leukocyte aggregates in patients with inflammatory bowel disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tekelioğlu Yavuz, Uzun Hikmet
Аннотация
BACKGROUND: Inflammatory bowel diseases (IBDs), Crohn's disease, and ulcerative colitis are considered to be chronic inflammatory disorders implicated with recurrent tissue damage to the intestine. There is a positive correlation between platelet-leukocyte aggregates and ischemic vascular risk. There are limited data about the relationship between platelet-leukocyte aggregates and IBD. This study was designed to determine whether platelet-leukocyte aggregates increase in IBD, and whether a relationship exists between the elevation of platelet-leukocyte aggregates and disease activity.
METHODS: A total of 20 patients with IBD (16 with ulcerative colitis and 4 with Crohn's disease) and 20 healthy controls participated in our study. Nine patients were in active-phase IBD, whereas 11 patients were in inactive phase. To show the presence of thrombocyte aggregates, the monoclonal antibodies such as Isotype IgG1 mouse antihuman CD42b-PE (phycoerythrin) (Beckman Coulter IMI417), Isotype IgG1 mouse antihuman CD45-FITC (fluorescein isothiocyanate) (Beckman Coulter IM0782), and Isotype IgG2a mouse antihuman CD45RO-FITC (Beckman Coulter IMI247) were used. Additionally, the values of platelet-neutrophil aggregates were measured in peripheral blood samples using flow cytometry techniques.
RESULTS: The levels of platelet-leukocyte aggregates in blood samples were found to be significantly higher during both the active and inactive phases in patients with IBD. There were no statistically significant differences between active-phase and inactive-phase patients.
CONCLUSION: We determined that the patient group had significantly higher platelet-leukocyte aggregate levels compared with the control group. This finding suggests that platelet-leukocyte aggregates may play a role in the development of IBD.
METHODS: A total of 20 patients with IBD (16 with ulcerative colitis and 4 with Crohn's disease) and 20 healthy controls participated in our study. Nine patients were in active-phase IBD, whereas 11 patients were in inactive phase. To show the presence of thrombocyte aggregates, the monoclonal antibodies such as Isotype IgG1 mouse antihuman CD42b-PE (phycoerythrin) (Beckman Coulter IMI417), Isotype IgG1 mouse antihuman CD45-FITC (fluorescein isothiocyanate) (Beckman Coulter IM0782), and Isotype IgG2a mouse antihuman CD45RO-FITC (Beckman Coulter IMI247) were used. Additionally, the values of platelet-neutrophil aggregates were measured in peripheral blood samples using flow cytometry techniques.
RESULTS: The levels of platelet-leukocyte aggregates in blood samples were found to be significantly higher during both the active and inactive phases in patients with IBD. There were no statistically significant differences between active-phase and inactive-phase patients.
CONCLUSION: We determined that the patient group had significantly higher platelet-leukocyte aggregate levels compared with the control group. This finding suggests that platelet-leukocyte aggregates may play a role in the development of IBD.